Company intelligence / Profile preview

EyRIS

Singapore, Singaporeeyris.io ↗

Ownership: Private
Development stage: Other

Overview

EyRIS has developed and commercialized an AI-powered deep learning system that analyzes retinal images to detect diabetic retinopathy, glaucoma suspect, and age-related macular degeneration. The platform is used in clinical practice, including national screening programs such as Brunei’s diabetic retinopathy initiative. No clinical trial data is specified, but the technology is actively deployed in real-world healthcare environments.

Therapeutic areas: Ophthalmology
Modalities: DeviceNon-pharmacological therapy (AI-based diagnostic software)
Industry: Medical Imaging

Partnerships

JPMCnova Sdn Bhd for Brunei national DR screening program rollout

Beyond the preview

Go deeper on EyRIS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyRIS.

Explore the full profile